PMID- 36152215
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221025
IS  - 2193-8210 (Print)
IS  - 2190-9172 (Electronic)
VI  - 12
IP  - 11
DP  - 2022 Nov
TI  - Adverse-Event Reports in Over-the-Counter Topical Acne Drug Products Containing 
      Benzoyl Peroxide from a Specific Pharmaceutical Company in the USA.
PG  - 2397-2400
LID - 10.1007/s13555-022-00808-9 [doi]
AB  - Benzoyl peroxide (BPO) has been used extensively in dermatology, often for the 
      treatment of acne vulgaris. In a 20-year period, dermatologists in the United 
      States used over-the-counter BPO more than 13 million times. However, skin 
      irritation and other adverse events (AEs) are associated with the use of BPO. AEs 
      associated with BPO were identified using the Galderma pharmacovigilance system, 
      which collects AE reports from multiple sources. Over approximately 20 years, 558 
      AE reports were collected from the database, ranging from application site 
      reactions to systemic hypersensitivity reactions, resulting in a reporting rate 
      of under 1%. These data show that the risk of OTC topical acne drug products 
      containing BPO is low.
CI  - (c) 2022. The Author(s).
FAU - Szymanski, Lydia
AU  - Szymanski L
AD  - Galderma Laboratories, Fort Worth, TX, 76177, USA.
FAU - Arekapudi, Krysten Lisella
AU  - Arekapudi KL
AD  - Galderma Laboratories, Fort Worth, TX, 76177, USA. 
      krysten.arekapudi@galderma.com.
LA  - eng
PT  - Letter
DEP - 20220924
PL  - Switzerland
TA  - Dermatol Ther (Heidelb)
JT  - Dermatology and therapy
JID - 101590450
PMC - PMC9588102
OTO - NOTNLM
OT  - Acne
OT  - BPO
OT  - Benzoyl peroxide
OT  - Rosacea
OT  - Tolerability
OT  - Topical
EDAT- 2022/09/25 06:00
MHDA- 2022/09/25 06:01
PMCR- 2022/09/24
CRDT- 2022/09/24 11:28
PHST- 2022/07/27 00:00 [received]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/09/25 06:00 [pubmed]
PHST- 2022/09/25 06:01 [medline]
PHST- 2022/09/24 11:28 [entrez]
PHST- 2022/09/24 00:00 [pmc-release]
AID - 10.1007/s13555-022-00808-9 [pii]
AID - 808 [pii]
AID - 10.1007/s13555-022-00808-9 [doi]
PST - ppublish
SO  - Dermatol Ther (Heidelb). 2022 Nov;12(11):2397-2400. doi: 
      10.1007/s13555-022-00808-9. Epub 2022 Sep 24.